GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).

Direct download: GRACEcast-336_ASCO_2015_SCLC_Patients_Immunotherapy_Benefit.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.


Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?


The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?


Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?

Direct download: GRACEcast-332_ASCO_2015_Immunotherapy_Opdivo_Squamous_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 4:39pm PST

Radiation Oncologist Dr. Vivek Mehta reviews the concept of using whole brain radiation for multiple brain metastases, including how it is delivered and risks and benefits of this strategy.

Direct download: GRACEcast-331_GCVL_LU-CA02_WBRT_Brain_Metastases.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Dr. Jack West reviews new techniques for evaluating mutations from blood, including detection of circulating tumor cells (CTCs) or mutations in circulating free DNA (cfDNA) that can replace at least some tissue biopsies.

Direct download: GRACEcast-330_GCVL_LU-B10_Liquid_Biopsy_Circulating_Free_DNA.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST